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Objectives: Pill dysphagia is common and costly with a significant risk of pill retention,
caustic injury, and poor medication compliance. The purpose of this investigation was
to determine the validity and reliability of the PILL-5, a self-administered patient reported
outcome measure (PROM) to quantify the degree of pill (tablet and capsule) dysphagia.
The PILL-5 is a 5-item questionnaire with a maximum symptom score of 20.
Methods: The PILL-5 was administered to 190 patients with dysphagia referred for
videofluoroscopic esophagography (VFE). Construct validity was assessed by comparing
PILL-5 composite scores to delayed barium tablet transit on VFE. Normative data was
obtained by administering the instrument to a cohort of healthy community based
volunteers. Internal consistency was assessed with the Cronbach alpha. Test/retest
reliability was determined by administering the instrument to the same cohort of patients
at two time points.
Results: The mean PILL-5 was 5.6 (±4.9) for persons with dysphagia and 1.6 (±2.7)
for healthy volunteers (p < 0.001). The internal consistency of the instrument was high
(Cronbach alpha = 0.85). The mean PILL-5 was 4.3 (±4.1) for patients with normal
transit and 7.6 (±5.3) for patients with delayed barium tablet transit on esophagography,
indicating excellent criterion based validity (p < 0.001). Reproducibility was high with an
intraclass correlation coefficient of 0.83 (p < 0.001).
Conclusions: Healthy individuals report some degree of swallowing difficulty with pills.
Normative data suggest that a PILL-5 > 6 is abnormal (mean + 2 SD). The instrument
demonstrated excellent criterion based validity and reliability. The PILL-5 is the first
validated patient reported outcome measure for pill dysphagia.
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INTRODUCTION
Pill dysphagia, or difficulty swallowing tablets or capsules, is a common problem with significant
health implications. Pill dysphagia can result from oropharyngeal sensory and motor deficits (1),
esophageal strictures, webs, and rings, motility disorders (2), and phagophobia (3, 4). A 2003 survey
of United States adults reported that ∼40% of respondents had experienced difficulty swallowing
pills (5). Pill dysphagia can result in pill retention, caustic injury (6, 7), pill aspiration (8, 9), and
poor medication compliance (10, 11). To manage difficulty swallowing pills, alternate methods
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of drug delivery have been developed, including oral
disintegrating tablets as well as liquid, nasal, pulmonary,
and transdermal formulations (12). Patients and caregivers
often modify tablets by splitting or crushing them. This practice
can affect the biopharmaceutical features of medications and
their effectiveness, creating a risk of adverse reaction (13, 14).
Despite the high prevalence of pill dysphagia and its negative
consequences, no self-administered patient reported outcome
measure (PROM) for the severity of pill dysphagia currently
exists. The purpose of this investigation was to determine the
validity and reliability of the PILL-5, a 5-item self-administered
patient PROM to quantify the degree of pill dysphagia.
METHODOLOGY
The study was approved by the University of California,
Davis Institutional Review Board (IRB). Written informed
consent was obtained from all patient participants. A waiver
of written consent was obtained from the UC Davis IRB for
healthy participants, on the basis that the questionnaires were
anonymous and could not be directly or indirectly identified.
Verbal consent was obtained from these healthy individuals
after providing them with a written information sheet per
IRB protocol.
The PILL-5 is a 5-item Likert questionnaire with maximum
(greatest symptoms) score of 20 (Table 1). The questions were
originally derived from a list of 10 questions developed by expert
consensus and obtained by the Delphi method, a systematic
survey method to collect opinions from a panel of experts and
reach consensus. The questions demonstrated high face validity
and were abridged to a 5-item final version based on line-
item redundancy. The questions address the localization of pill
retention and the degree of disability (Table 1). Subjects were
instructed to rate how frequently they experienced difficulty with
swallowing pills by circling zero for never up to four for always.
The PILL-5 was administered to 190 patients with
dysphagia referred for videofluoroscopic esophagography
(VFE). Normative data was obtained by administering the
instrument to a cohort (n = 226) of healthy community based
volunteers. This healthy cohort had no history of swallowing
dysfunction, gastroesophageal reflux, or other gastrointestinal
TABLE 1 | PILL-5 assessment tool.
Please circle the response that indicates how frequently you experience
these symptoms.
0 = Never; 1 = Almost Never; 2 = Sometimes; 3 = Almost Always; 4 = Always
1. Pills stick in my throat 0 1 2 3 4
2. Pills stick in my chest 0 1 2 3 4
3. I have a fear of swallowing pills 0 1 2 3 4
4. My problem swallow pills interferes with
my ability to take my medicine
0 1 2 3 4
5. I can’t take my pills without crushing,
coating, or using other forms of
assistance
0 1 2 3 4
disease, neurologic, or myopathic disease, or cancer of the head
and neck, chest, or gastrointestinal tract.
Criterion-based validity of the instrument was assessed by
comparing PILL-5 composite scores to delayed barium tablet
transit on VFE. The VFE studies were completed in accordance
with the standard protocol at our institution. Each subject was
administered a bolus of liquid barium (EZ-PAQUE barium
sulfate suspension, 60% w/v; 41% w/w, E-Z-EM, Inc., Westbury,
NY) of 1, 20mL in the lateral seated position and a 20ml liquid
barium bolus and 13mm barium tablet (EZ Disk Barium Sulfate
Tablet, Bracco Diagnostics, Monroe Township, NJ) in the AP
standing position. Patients were then instructed to drink a 20mL
single swallow of barium followed by consecutive swallows of
∼100mL of barium from a cup sip in the right anterior oblique
position. Finally, a water siphon test was performed in the supine
position to evaluate for gastroesophageal reflux.
The anatomic structures and function of the
pharyngoesophageal segment (PES) and esophagus were
evaluated. Barium tablet transit was measured from the moment
a verbal instruction to swallow was given until entry of the tablet
into the stomach. Subjects were divided into groups of those with
less than and those with more than 15 s of tablet transit. VFE
recordings were analyzed by two independent raters blinded to
the PILL-5 scores. A subset of 20 (10%) studies were analyzed
by both raters in order to assess inter-rater reliability. PILL-5
composite scores of the normal and abnormal tablet transit
groups were compared using the independent samples t-test.
In order to assess test-retest reproducibility of the instrument,
the PILL-5 was administered to a subset of individuals (N = 74)
on a second occasion at least 48 h and amaximum of 30 days after
the initial administration. The intraclass correlation coefficient




The internal consistency of the instrument was high (Cronbach
alpha= 0.85). Test-retest reliability was strong, with an intraclass
correlation coefficient of 0.83 (p < 0.001).
Normative Data
The mean (± SD) age of the healthy population (n= 226) was 49
(±18.6) years and 32% (n = 73) was male. The mean (±SD) age
of the healthy participants aged 40 or above (n = 140) was 61.5
(±12.4) and 39% (n= 54) of the group was male (see Tables 2, 3
for patient characteristics).
The mean (± SD) PILL-5 of the normal cohort was 1.6 (±
2.7) (Table 3). The data was normally distributed and a Pill 5 > 6
(Mean+ 2 SD) represents the top 5% of responses.
Construct Validity
The mean age of the patient population with dysphagia (n
= 190) was 61.2 (±13.2) years and 42% (n = 79) was male.
The mean total PILL-5 score for patients with dysphagia was
5.6 (±4.9). This was significantly higher than the PILL-5 of
the normal population (p < 0.001) with a large effect size
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(Cohen’s d = 1.03). The groups differed significantly on all items
of the PILL-5 questionnaire (p < 0.001, Table 3). The mean
(±SD) PILL-5 for patients with delayed barium tablet transit on
esophagography was 7.58 (±5.3) in comparison to 4.3 (±4.1) for
patients with normal barium tablet transit, indicating excellent
criterion based validity (p < 0.001). The interrater reliability
between the two clinicians assessing barium tablet transit times
was high (κ= 0.86).
DISCUSSION
Pill dysphagia is common and costly (1, 10, 15). A recent survey
suggests that four out of five adult Americans take several pills
each day and nearly half report difficulty swallowing pills (11).
Pill dysphagia is even more problematic in the elderly, who suffer
a high prevalence of swallowing difficulty and are prescribed a
large number of oral medications (16). Pill dysphagia can result
in low medication adherence and treatment failure (17). In a
survey of 540 nursing home residents, 15% of all inhabitants
reported difficulty swallowing tablets and capsules. Of this group,
5% regularly expectorated their medication, while 27% refrained
altogether from taking their medications (10). These findings are
supported by the data from our investigation and suggest that
some degree of baseline pill dysphagia is experienced by a large
percentage of healthy adults.
Pill dysphagia can result in adverse outcomes. Stasis of tablets
or capsules in the esophagus can affect the pharmacokinetics
of medications and reduce effectiveness. Delayed transit may
lead to premature drug-release, which reduces bioavailability
and drug degradation (18). Moreover, pill retention can cause
caustic injury due to prolonged contact of the medication
with the esophageal mucosa (19–21). This can cause stricture
formation, retrosternal pain, dysphagia, odynophagia, and in rare
cases, can lead to complications such as mediastinal penetration,
hemorrhage, and death (21). A recent report highlighted the
TABLE 2 | Distribution of patient diagnoses.
Diagnostic category Number of subjects
Neurodegenerative/neuromuscular 8
Neurological Insult 2
Cervical spine abnormalities 12
Gastroesophageal Reflux Disease (GERD) 21
Esophageal dysmotility 26
Cricopharyngeal Muscle Dysfunction (CPMD) 84
Dysphagia-uncertain etiology 37
dangers of the common recommendation of nil per os except
medications given to patients with dysphagia, which puts patients
at risk for pill aspiration and its consequences (8).
In recent decades, several global dysphagia self-assessment
tools have emerged (22–24), however no self-administered
assessment tool for pill dysphagia exists. Due to the unique
clinical manifestations of pill dysphagia and the propensity
for pill dysphagia to manifest without liquid or solid food
dysphagia, there is a need for a tool focused specifically on
defining pill dysphagia symptoms and its impact on patients. A
recent investigation of persons admitted to an inpatient geriatric
ward revealed that over 95% of patients with dysphagia were
prescribed a solid formulation of medication that was potentially
inappropriate for the degree of swallowing impairment with
an average of nearly 2.5 inappropriate prescriptions per patient
(25). A diagnostic tool specific for pill dysphagia can assist with
safer and more efficacious prescribing habits. The advantage of a
validated PROM over a simple binomial query of pill dysphagia
(yes/no) is that the degree of swallowing impairment with pills
can be quantified. This will allow clinicians to assess baseline pill
dysphagia severity and alter their prescribing habits accordingly.
In our experience, patients with minimal or no pill dysphagia
(PILL-5 < 6) require no medication alteration, patients with
mild to moderate pill dysphagia (PILL-5 ≥ 6 and < 12) can
be managed with pill lubricants, and patients with moderate
to severe pill dysphagia (PILL-5 ≥ 11) may require an altered
formulation of medication. Appropriate referral to a swallowing
specialist is warranted in individuals with a PILL-5 ≥ 6 to rule
out obstructing pathology such an esophageal or cricopharyngeal
stricture or web that may be easily treatable.
The data from this investigation suggest that the validity
and reliability of the PILL-5 is high and that the instrument
can differentiate between healthy controls and individuals with
delayed barium tablet transit on swallowing fluoroscopy. Healthy
volunteers without any history of swallowing difficulty reported
a mean PILL-5 of 1.6 (±2.7). This suggests that some degree of
difficulty swallowing pills is normal for most individuals. This
is in contrast to dysphagia for solids and liquids, which are not
typically experienced by healthy controls (23).
A limitation of the study is that the questionnaire was
administered to patients who were referred for a VFE in a
tertiary center. These patients may have clinical characteristics
that are different from other patients with swallowing difficulty.
Administration of the questionnaire to additional patient
populations with and without dysphagia may demonstrate
differences in subgroup PILL-5 scores. The cutoff of a PILL-5≥ 6
(mean+ 2 SD) provides a conservative estimate for an abnormal
TABLE 3 | Statistical summary of the PILL-5.
Q1 Q2 Q3 Q4 Q5 Total
Patients with dysphagia 1.9 (±1.2)* 0.9 (±1.1)* 1.2 (±1.4)* 0.9 (±1.3)* 0.7 (±1.2)* 5.6 (±4.9)*
Normal cohort ≥40 years old 0.6 (±0.9)* 0.3 (±0.7)* 0.2 (±0.7)* 0.2 (±0.5)* 0.3 (±0.9)* 1.5 (±2.8)*
Normal cohort all ages 0.7 (±0.9)* 0.3 (±0.7)* 0.3 (±0.8)* 0.2 (±0.5)* 0.2 (±0.8)* 1.6 (±2.7)*
Values are mean ± SD. Asterisk denotes statistically significant differences between patient and control cohorts.
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instrument. Utilization of this cutoffmaymiss some patients with
mild pathologic pill dysphagia.
CONCLUSION
The PILL-5 is the first validated and reliable patient reported
outcome measure for pill (capsule and tablet) dysphagia.
Normative data suggest that a PILL-5 >6 is significantly
abnormal (mean+2 SD). The instrument demonstrated excellent
criterion based validity and test-retest reliability.
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